Developer docs
API playgroundTry for free, no card

Search company profiles

Minoryx Therapeutics

Full company profile

uuid0000rtw

Namestring
Minoryx Therapeutics
Legal namestring
MINORYX THERAPEUTICS SL
Websiteurl
minoryx.com
Company typeenum
Private
Founded yearint
2011
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMataró, Spain
HQ citystring
Mataró
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orphan CNS therapeutics, PPAR gamma agonists, rare disease drug development, neurodegenerative disease treatments, X-linked adrenoleukodystrophy drugs
Industry1 code
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Orphan CNS Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Pre-revenue biotech company. Once approved, the company will generate revenue through sales of leriglitazone (brand name NEZGLYAL®). Neuraxpharm holds exclusive license for Europe, Sperogenix holds license for China. Revenue model will be traditional pharmaceutical product sales through prescription.

minoryx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1NEZGLYAL®
Description

Brand name for leriglitazone, the company's lead drug candidate for treatment of cerebral adrenoleukodystrophy (cALD)

minoryx.com
Core offering1 text field

Minoryx Therapeutics is a clinical-stage biotech company developing leriglitazone (MIN-102/NEZGLYAL®), a novel, orally bioavailable, selective PPAR gamma agonist for the treatment of orphan central nervous system (CNS) diseases. The lead indication is X-linked Adrenoleukodystrophy (X-ALD), with ongoing clinical programs in Friedreich's Ataxia and Rett syndrome. The company is pursuing EMA and FDA regulatory approval and licensing commercialization to regional pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 35% of evaluable cALD patients met arrested disease criteria vs 10% expected from natural history (p<0.05) in NEXUS trial
+4 more records
Product overview1 text field

Minoryx Therapeutics is a clinical-stage biotech company developing leriglitazone (MIN-102/NEZGLYAL®), a novel selective PPAR gamma agonist for orphan CNS diseases. The lead compound is being advanced through multiple clinical trial programs: ADVANCE (phase 2/3 in X-ALD adult patients), NEXUS (phase 2/3 in pediatric cALD), CALYX (phase 3 in adult progressive cALD), FRAMES (phase 2 in Friedreich's Ataxia), and TREE (phase 2a in Rett syndrome). The company has submitted a Marketing Authorization Application to EMA for cALD treatment.

Product and service1 record
1Leriglitazone (MIN-102/NEZGLYAL®)
CategoryOrphan CNS Therapeutics
Description

Novel, orally bioavailable, selective PPAR gamma agonist with demonstrated brain penetration and favorable safety profile. Being developed for X-linked Adrenoleukodystrophy (X-ALD) including cerebral ALD (cALD) and adrenomyeloneuropathy (AMN), Friedreich's Ataxia, and Rett syndrome. Has been granted FDA Orphan Drug Designation, EMA Orphan Drug Designation, FDA Fast Track Designation, and FDA Rare Pediatric Disease Designation for X-ALD. Patents granted in EU and US covering multiple CNS indications until 2039.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Neuraxpharm Group
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Neuraxpharm holds exclusive license for leriglitazone (NEZGLYAL®) in Europe. The partnership includes commercialization rights where Neuraxpharm prepares for and executes the commercial launch in Europe. Neuraxpharm is a leading European specialty pharmaceutical company focused on CNS disorders with direct presence in 20+ countries. They are backed by funds advised by Permira.

minoryx.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Sperogenix has licensed rights to leriglitazone for China, handling commercialization in that market.

3Hôpital Universitaire La Pitié-Salpêtrière
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Led compassionate use study of leriglitazone in 13 adult cALD patients in France as part of early-access program through ANSM (French national drug agency). Study led by Prof. Fanny Mochel, published results in Brain journal.

minoryx.com
4Hospital Sant Joan de Déu
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Barcelona hospital conducting TREE clinical trial in Rett syndrome under direction of Dr. Ángeles García Cazorla. Study funded by MCIN/AEI/10.13039/501100011033 and Union Europea-NextGenerationEU/PRTR.

minoryx.com
5ALD Connect
Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient advocacy organization for X-linked Adrenoleukodystrophy. Kathleen O'Sullivan-Fortin, Co-Founder, expressed community excitement about CALYX trial commencement for adult cALD where few options are available.

minoryx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

French clinical-stage biotech focused on rare metabolic and neurological diseases, with direct overlap in Friedreich's Ataxia (PXL065 program). Comparable stage, European base, and indication focus to Minoryx.

TypeBroad incumbent
Description

Rare disease company with both metabolic and CNS pipeline programs including sparsentan and Filspari. Comparable mid-cap rare disease biotech with parallel platform expansion strategy.

TypeDirect peer
Description

Clinical-stage rare neurological disease biotech developing antisense oligonucleotide (ASO) therapies including zorevunersen for Dravet syndrome. Comparable late-stage rare CNS development profile and platform-based approach.

TypeBroad incumbent
Description

Established rare disease leader with multiple CNS and metabolic franchises (including Voxzogo). Larger incumbent with proven rare disease commercialization infrastructure across the same orphan prescribers Minoryx targets.

5bluebird bio
TypeDirect peer
Description

Obtained initial FDA approval for Skysona (elivaldogene autotemcel) gene therapy in early active cALD. Directly competes with leriglitazone for the same X-ALD patient population, representing Minoryx's most direct competitor in lead indication.

TypeBroad incumbent
Description

Established antisense-based rare neurological disease developer with multiple approved therapies (Spinraza, Tegsedi, Wainua). Represents a broader incumbent in the rare CNS disease therapeutic space.

TypeBroad incumbent
Description

CNS-focused biotech developing novel therapies for rare neurological disorders (Zulresso, Zurzuvae). Comparable CNS-focused clinical pipeline orientation and small-molecule orphan neurology focus.

TypeBroad incumbent
Description

Commercial-stage rare disease biotech with approved products across metabolic and CNS indications. Comparable platform approach of single asset expanded across multiple rare diseases, with deeper financial resources.

TypeDirect peer
Description

Developed Skyclarys (omaveloxolone) for Friedreich's Ataxia, the first FDA-approved therapy for FRDA. Direct competitor in Minoryx's second indication with an already-launched and approved product.

10MedDay Pharmaceuticals
TypeDirect peer
Description

Paris-based biotech that developed DILA-VR/serdexmethylphenidate for X-ALD-adjacent indications. Closely comparable European rare CNS biotech with similar indication footprint and development stage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Minoryx Therapeutics

Orphan CNS Therapeuticsminoryx.com

Minoryx Therapeutics firmographics

Firmographics
Name
Minoryx Therapeutics
Legal name
MINORYX THERAPEUTICS SL
Website
https://minoryx.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Minoryx Therapeutics industry classification

Industry
Product category
Orphan CNS Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Orphan CNS therapeutics
  • PPAR gamma agonists
  • Rare disease drug development
  • Neurodegenerative disease treatments
  • X-linked adrenoleukodystrophy drugs

Where Minoryx Therapeutics is headquartered

Location

Headquarters

HQ city
Mataró
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Minoryx Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical product sales: Pre-revenue biotech company. Once approved, the company will generate revenue through sales of leriglitazone (brand name NEZGLYAL®). Neuraxpharm holds exclusive license for Europe, Sperogenix holds license for China. Revenue model will be traditional pharmaceutical product sales through prescription.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Minoryx Therapeutics product offering

Product offering

Core offering

Minoryx Therapeutics is a clinical-stage biotech company developing leriglitazone (MIN-102/NEZGLYAL®), a novel, orally bioavailable, selective PPAR gamma agonist for the treatment of orphan central nervous system (CNS) diseases. The lead indication is X-linked Adrenoleukodystrophy (X-ALD), with ongoing clinical programs in Friedreich's Ataxia and Rett syndrome. The company is pursuing EMA and FDA regulatory approval and licensing commercialization to regional pharmaceutical partners.

Product overview

Minoryx Therapeutics is a clinical-stage biotech company developing leriglitazone (MIN-102/NEZGLYAL®), a novel selective PPAR gamma agonist for orphan CNS diseases. The lead compound is being advanced through multiple clinical trial programs: ADVANCE (phase 2/3 in X-ALD adult patients), NEXUS (phase 2/3 in pediatric cALD), CALYX (phase 3 in adult progressive cALD), FRAMES (phase 2 in Friedreich's Ataxia), and TREE (phase 2a in Rett syndrome). The company has submitted a Marketing Authorization Application to EMA for cALD treatment.

Differentiator

Problem solved

Functional benefit

Brands

  • NEZGLYAL®: Brand name for leriglitazone, the company's lead drug candidate for treatment of cerebral adrenoleukodystrophy (cALD)

Products and services

  • Leriglitazone (MIN-102/NEZGLYAL®) Novel, orally bioavailable, selective PPAR gamma agonist with demonstrated brain penetration and favorable safety profile. Being developed for X-linked Adrenoleukodystrophy (X-ALD) including cerebral ALD (cALD) and adrenomyeloneuropathy (AMN), Friedreich's Ataxia, and Rett syndrome. Has been granted FDA Orphan Drug Designation, EMA Orphan Drug Designation, FDA Fast Track Designation, and FDA Rare Pediatric Disease Designation for X-ALD. Patents granted in EU and US covering multiple CNS indications until 2039.

Quantifiable outcome

  • 35% of evaluable cALD patients met arrested disease criteria vs 10% expected from natural history (p<0.05) in NEXUS trial
  • +4 more outcomes

Companies that use Minoryx Therapeutics

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Minoryx Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Minoryx Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Neuraxpharm GroupcoreChannel Partner/ Reseller/ DistributorNeuraxpharm holds exclusive license for leriglitazone (NEZGLYAL®) in Europe. The partnership includes commercialization rights where Neuraxpharm prepares for and executes the commercial launch in Europe. Neuraxpharm is a leading European specialty pharmaceutical company focused on CNS disorders with direct presence in 20+ countries. They are backed by funds advised by Permira.
  • SperogenixminorChannel Partner/ Reseller/ DistributorSperogenix has licensed rights to leriglitazone for China, handling commercialization in that market.
  • Hôpital Universitaire La Pitié-SalpêtrièrecoreStrategic or Co-development PartnerLed compassionate use study of leriglitazone in 13 adult cALD patients in France as part of early-access program through ANSM (French national drug agency). Study led by Prof. Fanny Mochel, published results in Brain journal.
  • Hospital Sant Joan de DéucoreStrategic or Co-development PartnerBarcelona hospital conducting TREE clinical trial in Rett syndrome under direction of Dr. Ángeles García Cazorla. Study funded by MCIN/AEI/10.13039/501100011033 and Union Europea-NextGenerationEU/PRTR.
  • ALD ConnectminorGTM or Marketing PartnerPatient advocacy organization for X-linked Adrenoleukodystrophy. Kathleen O'Sullivan-Fortin, Co-Founder, expressed community excitement about CALYX trial commencement for adult cALD where few options are available.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Minoryx Therapeutics competitors and assessment

Company assessment

Direct peers

  • Poxel SA: French clinical-stage biotech focused on rare metabolic and neurological diseases, with direct overlap in Friedreich's Ataxia (PXL065 program). Comparable stage, European base, and indication focus to Minoryx.
  • Stoke Therapeutics: Clinical-stage rare neurological disease biotech developing antisense oligonucleotide (ASO) therapies including zorevunersen for Dravet syndrome. Comparable late-stage rare CNS development profile and platform-based approach.
  • bluebird bio: Obtained initial FDA approval for Skysona (elivaldogene autotemcel) gene therapy in early active cALD. Directly competes with leriglitazone for the same X-ALD patient population, representing Minoryx's most direct competitor in lead indication.
  • Reata Pharmaceuticals: Developed Skyclarys (omaveloxolone) for Friedreich's Ataxia, the first FDA-approved therapy for FRDA. Direct competitor in Minoryx's second indication with an already-launched and approved product.
  • MedDay Pharmaceuticals: Paris-based biotech that developed DILA-VR/serdexmethylphenidate for X-ALD-adjacent indications. Closely comparable European rare CNS biotech with similar indication footprint and development stage.

Broad incumbents

  • Travere Therapeutics: Rare disease company with both metabolic and CNS pipeline programs including sparsentan and Filspari. Comparable mid-cap rare disease biotech with parallel platform expansion strategy.
  • BioMarin Pharmaceutical: Established rare disease leader with multiple CNS and metabolic franchises (including Voxzogo). Larger incumbent with proven rare disease commercialization infrastructure across the same orphan prescribers Minoryx targets.
  • Ionis Pharmaceuticals: Established antisense-based rare neurological disease developer with multiple approved therapies (Spinraza, Tegsedi, Wainua). Represents a broader incumbent in the rare CNS disease therapeutic space.
  • Sage Therapeutics: CNS-focused biotech developing novel therapies for rare neurological disorders (Zulresso, Zurzuvae). Comparable CNS-focused clinical pipeline orientation and small-molecule orphan neurology focus.
  • Ultragenyx Pharmaceutical: Commercial-stage rare disease biotech with approved products across metabolic and CNS indications. Comparable platform approach of single asset expanded across multiple rare diseases, with deeper financial resources.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Minoryx Therapeutics social profiles

Digital presence

Minoryx Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Minoryx Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Minoryx Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Minoryx Therapeutics funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Minoryx Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Minoryx Therapeutics

What does Minoryx Therapeutics do?

Minoryx Therapeutics is a clinical-stage biotech company developing leriglitazone (MIN-102/NEZGLYAL®), a novel, orally bioavailable, selective PPAR gamma agonist for the treatment of orphan central nervous system (CNS) diseases. The lead indication is X-linked Adrenoleukodystrophy (X-ALD), with ongoing clinical programs in Friedreich's Ataxia and Rett syndrome. The company is pursuing EMA and FDA regulatory approval and licensing commercialization to regional pharmaceutical partners.

Is Minoryx Therapeutics a public or private company?

Minoryx Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Minoryx Therapeutics founded?

Minoryx Therapeutics was founded in 2011. It employs 11 to 50 people.

Where is Minoryx Therapeutics based?

Minoryx Therapeutics is headquartered in Mataró, Spain, in the Europe region.

How does Minoryx Therapeutics make money?

One revenue line is on record: pharmaceutical product sales.

Who are Minoryx Therapeutics's main competitors?

Direct peers on record are Poxel SA, Stoke Therapeutics, bluebird bio, Reata Pharmaceuticals and MedDay Pharmaceuticals. Broad incumbents are Travere Therapeutics, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Sage Therapeutics and Ultragenyx Pharmaceutical.

Does Minoryx Therapeutics have an API?

No public API is recorded for Minoryx Therapeutics.

What industry is Minoryx Therapeutics in?

Minoryx Therapeutics's product category is Orphan CNS Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmaTimesNezglyal approved in EU for childhood cALDThe European Commission granted marketing authorization for Nezglyal to treat male childhood cerebral adrenoleukodystrophy with Gd-negative brain lesions. It is the first pharmacological therapy for this disease, with the first launch in Germany expected by the end of 2026. Further launches will follow national reimbursement negotiations.PharmaTimesNezglyal receives positive CHMP opinion supporting treatment access for boys with cALDThe European Medicines Agency's CHMP recommended marketing authorisation for Nezglyal to treat male cerebral adrenoleukodystrophy patients aged 2-12 with gadolinium-negative brain lesions. European Commission approval is expected by September 2026, with no approved pharmacological treatments for cALD in the EU. The development programme continues with ongoing trials.PMLiVEEMA recommends granting marketing authorisation approval for NezglyalEMA's CHMP has recommended granting marketing authorisation under exceptional circumstances for Nezglyal (leriglitazone), a treatment for cerebral adrenoleukodystrophy (cALD) developed by Minoryx Therapeutics and to be commercialised in Europe by Neuraxpharm Group. European Commission approval is expected by the end of September 2026, and there are currently no approved pharmacological treatments for cALD in the EU. The development programme continues with the ongoing CALYX phase 3 trial in adult male cALD patients and the TREE3 phase 2a trial in Rett syndrome.pharmaphorumJ&J's oral IL-23 drug backed for psoriasis in EUThe EMA's CHMP recommended Johnson & Johnson's oral IL-23 inhibitor Icotyde for plaque psoriasis in patients aged 12 and over weighing at least 40kg. The drug, the first oral IL-23 inhibitor, showed about two-thirds of recipients achieving clear or almost clear skin versus 8-11% with placebo. It was cleared for marketing in the US weeks earlier.Endpoints NewsCHMP recommends Minoryx’s ALD drug, rejects Zevra’s MeplyffaThe European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended Minoryx Therapeutics' neurological drug for adrenoleukodystrophy (ALD), ending a period of multiple regulatory hurdles for the company. In contrast, Zevra received a CHMP rejection for its rare disease drug Meplyffa, representing a setback for the company's product pipeline.EXPANSIONMinoryx obtiene el visto bueno de la EMA para su fármaco estrellaThe European Medicines Agency's committee for medicinal products for human use has issued a positive opinion recommending conditional marketing authorization for Nezgyal, developed by Minoryx Therapeutics in partnership with Neuraxpharm, for the treatment of cerebral adrenoleukodystrophy in male patients aged 2-12 with non-gadolinium-enhancing brain lesions. The companies expect the European Commission to grant final approval by the end of September, after signing a 258-million-euro licensing agreement in 2022. Minoryx, founded in 2011 and headquartered in Mataró, Barcelona, has raised over 150 million euros from venture capital and institutional investors, while Neuraxpharm maintains its seat in Düsseldorf with production facilities in Barcelona.European BiotechnologyCHMP backs Minoryx’s rare disease drug two years after rejectionThe European Medicines Agency's CHMP recommended approval for Minoryx's rare disease drug Nezglyal, two years after an earlier rejection. The recommendation covers boys aged 2-12 with early-stage, non-gadolinium-enhancing brain lesions, based on the NEXUS trial where 35% of evaluable boys had arrested disease. The European Commission will make the final authorization decision.BioSpaceNEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative diseaseThe EMA's CHMP recommended marketing authorisation for NEZGLYAL (leriglitazone) for male cALD patients aged 2-12 with Gd-negative brain lesions. European Commission approval is expected by end of September 2026, based on NEXUS trial and real-world data. The companies plan US approval and label expansion.openPR.comFriedreich's Ataxia Pipeline Enters a Transformative Era with 20+ Therapies and Strong Clinical Momentum from Larimar Therapeutics, Minoryx Therapeutics, and Design Therapeutics | DelveInsightDelveInsight's Friedreich's Ataxia Pipeline Insight 2026 report identifies over 20 active therapeutic candidates and more than 18 companies advancing treatments for the rare neurodegenerative disorder. Key regulatory and clinical developments include Solid Biosciences receiving FDA Orphan Drug designation for SGT-212 and dosing the first participant in a Phase 1b trial in January 2026, PTC Therapeutics receiving a Complete Response Letter for its vatiquinone NDA in August 2025, and Biogen initiating a global Phase 3 BRAVE study for omaveloxolone in June 2025.openPR.comAdrenoleukodystrophy Drugs Market to Cross US$ 2.3 Billion by 2035 Driven by Advancements in Gene Therapy and Rare Disease TreatmentsThe global adrenoleukodystrophy (ALD) drugs market was valued at US$ 519.4 million in 2024 and is projected to cross US$ 2.3 billion by 2035, expanding at a compound annual growth rate (CAGR) of 13.9%. Growth is driven by advancements in gene therapy, increasing investment in rare disease research, and expanding newborn screening programs. In May 2024, the EMA's CHMP recommended against granting marketing authorization for Minoryx Therapeutics' NEZGLYAL (leriglitazone) for childhood cerebral ALD.